Structural and functional characterization of novel F7 mutations identified in Chinese factor VII ‐ deficient patients
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18768 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Can Lou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: East Asian People, Factor VII, Factor VII Deficiency. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hereditary factor VII (FVII) deficiency is a rare recessive bleeding disorder with an estimated prevalence of 1/500 000. We had investigated 50 unrelated Chinese patients with FVII deficiency and identified, in total, 25 mutations, including 18 missense mutations and 5 splicing mutations, on the F7 gene. The nucleotide transition c.1224T>G (p.His408Gln) in exon 9 constitutes a hotspot of mutation, with 19 patients harbouring this genetic variance. Few patients were homozygous or compound heterozygous for deleterious mutations, such as non‐sense mutations, large insertion or deletions, indicating that complete deficiency of FVII may not be compatible with life. The eight novel mutations identified in the study, including one small deletion (p.Glu49GlyfsTer101), three type I missense mutations, p.Cys238Phe, p.Gly420Asp, p.Ala252Val and four type II missense mutations, p.Val336Met, p.Ser342Gly, p.Gly432Ser and p.Ile213Asn, were further analysed by in vitro expression and functional studies. The laboratory phenotype and structural analysis confirmed the functional consequence of p.Ile213Asn mutation involving cleavage and activation site. The molecular dynamic simulations and binding energy calculations along with functional probing of p.Gly432Ser mutation revealed the critical role of residue Gly432 in the binding between activated factor VII (factor VIIa) and tissue factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Center for Clinical Laboratory, Shanghai, China.
- Department of Pediatric Hematology, The First Hospital Affiliated to Guangxi Medical University, Nanning, China.
- State Key Laboratory of Microbial Metabolism & Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
- Department of Geriatric Gastroenterology and Endocrinology, Shaanxi Provincial People's Hospital, Xi'an, China.
ORCID-Profile: Can Lou, Qiulan Ding, Xuefeng Wang, Wenman Wu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lou, C., Jiang, J., Chen, W., Zhang, Z., Xu, G., Liu, Y., Dai, J., Ding, Q., Wang, X., Wei, H., Wu, Y., Xu, Q., & Wu, W. (2023). Structural and functional characterization of novel F7 mutations identified in Chinese factor VII ‐ deficient patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18768
Vancouver
Lou C, Jiang J, Chen W, Zhang Z, Xu G, Liu Y, et al. Structural and functional characterization of novel F7 mutations identified in Chinese factor VII ‐ deficient patients. British Journal of Haematology. 2023. doi:10.1111/bjh.18768
BibTeX
@article{Lou2023,
author = {Lou, Can and Jiang, Jiali and Chen, Weizhi and Zhang, Zhili and Xu, Guanqun and Liu, Yu and Dai, Jing and Ding, Qiulan and Wang, Xuefeng and Wei, Hongying and Wu, Youwei and Xu, Qin and Wu, Wenman},
title = {Structural and functional characterization of novel F7 mutations identified in Chinese factor VII ‐ deficient patients},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18768}
}
EUVIMED